ABSI has ripped 56% in a single week to $11.59, yet the shorts have barely moved — setting up one of the more telling standoffs in small-cap biotech right now.
The short position is stubbornly large. Short interest climbed roughly 9.7% over the week to 22.3% of the free float — around 33.6 million shares — even as the stock was tearing higher. That is not a squeeze unwind. Shorts are holding, and in some cases adding, into a rally that would be causing acute pain on any meaningful leveraged position. The ORTEX short score has held in the low-70s all week, registering 73.3 on Tuesday, consistent with a heavily contested name rather than one where bears are capitulating. Days-to-cover stands at 6.7 per the most recent official FINRA data, meaning any genuine squeeze dynamic would take time to resolve even if sentiment flipped overnight.
The lending market tells a different story from the short-position data, and that contrast matters. Despite 22% short interest, borrow availability is surprisingly relaxed — running near 94% of outstanding short interest, meaning there is roughly one share available for every share already borrowed. Cost to borrow has actually drifted lower over the past month, now at 0.65%, down from above 0.90% in late May. The 52-week minimum availability hit 0.086% — near-total tightness — so the current reading is historically loose by comparison. Bears are not being squeezed out of the borrow market. They are staying put because the shares remain findable and cheap to hold.
Options positioning flags something new this week, and it is worth noting. The put/call ratio jumped to 0.114 on Tuesday — more than two and a half standard deviations above its 20-day average of 0.080, a z-score of 2.6. That is the most defensive options skew ABSI has seen in months, even as the stock was closing near its weekly high. Some participants are buying downside protection into the move rather than chasing calls. The 52-week PCR range runs from 0.048 to 0.396, so the reading is nowhere near extreme on an absolute basis, but the sharp one-week shift is notable given that the prior three weeks saw PCR grinding along the lower end of its range while the stock was rallying.
The analyst picture has shifted meaningfully since the previous note published June 24, when ABSI was at $7.41 and the contradiction was a falling stock against rising targets. HC Wainwright raised its target to $16 from $8 on June 25. The Street consensus now clusters between $11 and $16 across recent contributors, with the mean around $13. Every recent analyst action has been a raise or a fresh initiation at Buy/Outperform. At $11.59, ABSI is no longer deeply below the target range — Needham's $11 target is already at-the-money. The analyst recommendation differential factor scores in the 93rd percentile, still reflecting a nearly unanimous bullish lean. The bull case rests on ABS-201's interim Phase 1 data and a differentiated AI-driven biology platform with potential peak sales around $3 billion. Bears point to cash burn, no guarantee of successful partnerships, and a highly competitive clinical landscape.
Institutional ownership adds one interesting wrinkle. Founder and CEO Sean McClain sold roughly 60,000 shares on June 24 at $10.075 — the same day the previous article noted the stock was dropping. That sale now looks opportunistic given the subsequent rally, though the significance score assigned to it was low. Two Sigma added 1.48 million shares in Q1, and Marshall Wace built a new 1.2-million-share position in the same period — both pointing to growing quant and hedge fund interest on the long side heading into the move.
The next scheduled catalyst is Q2 earnings on August 7. The most recent earnings print on June 4 produced a 7.7% one-day gain and a 9.6% five-day follow-through — one of the cleaner post-print momentum setups in the recent history. Whether the shorts who held through a 56% weekly rally stay positioned into that event is the dynamic worth tracking closely over the next five weeks.
See the live data behind this article on ORTEX.
Open ABSI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
